I am very positive about the outcome. It will get approval to go into phase 3. Phase 3 will be paid by the money (2 million dollars now and in total 15million dollars) by a partnership for nanotech with Actavis. So when their current phase 3 product brings out good results in Q2 2014 and will be approved by the FDA, the commercialization will bring net profit and will not have to be used to pay for their other clinical studies.
Yesterdays' news was extermely important. Analyst will be recalculation their projections in the positive way. 7dollar/share will be too conservative as a year target.